Madopar Depot (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Benserazide inhibits the peripheral enzyme dopa‑decarboxylase, preventing levodopa from being metabolized before it reaches the brain, thereby increasing central dopamine availability.

The dose of Madopar Depot is individualized and determined by the prescribing clinician based on the patient's disease severity, response, and tolerability. Patients should follow the specific dosing regimen provided by their healthcare professional and not adjust the dose without medical advice.

Safety of Madopar Depot in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Madopar Depot, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Madopar Depot provides a prolonged‑release delivery of levodopa and benserazide, resulting in more stable plasma concentrations and potentially fewer dosing intervals compared with immediate‑release tablets. This can lead to smoother symptom control and may reduce the frequency of motor fluctuations in some patients.

Madopar Depot should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Madopar Depot is taken orally, usually with a glass of water. It is often recommended to take the medication with food to reduce gastrointestinal discomfort, but patients should follow the specific instructions given by their prescriber.

Serious risks include the development of dyskinesias, hallucinations or psychosis, severe hypotension or hypertension, cardiac arrhythmias, and rare but life‑threatening reactions such as neuroleptic malignant syndrome or anaphylaxis. Patients should be monitored closely for these events.

Madopar Depot is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with a history of severe cardiovascular instability unless specifically directed by a physician.